{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:28:49Z","timestamp":1761895729311},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1097\/med.0b013e32834a8726","type":"journal-article","created":{"date-parts":[[2013,8,30]],"date-time":"2013-08-30T16:11:58Z","timestamp":1377879118000},"page":"321-327","source":"Crossref","is-referenced-by-count":8,"title":["Is there a path for approval of an antiobesity drug"],"prefix":"10.1097","volume":"18","author":[{"given":"Morgan","family":"Downey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Still","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arya M.","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-8-20211004","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0140-6736(10)62037-5","article-title":"National, regional and global trends in body mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants.","volume":"377","author":"Finucane","year":"2011","journal-title":"Lancet"},{"key":"R2-8-20211004","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1136\/bmj.c824","article-title":"Withdrawal of sibutramine in Europe.","volume":"340","author":"Williams","year":"2010","journal-title":"BMJ"},{"key":"R3-8-20211004","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/BF02245152","article-title":"A comparison of the effects of sibutramine hydrochloride, bupropion and methamphetamine on dopaminergic function: evidence that dompanine is not a pharmacological target for sibutramine.","volume":"107","author":"Heal","year":"1992","journal-title":"Psychopharmacology (Berl)"},{"key":"R4-8-20211004","first-page":"95","article-title":"The use of serotonergic drugs to treat obesity: is there any hope Drug Design Dev T","volume":"5","author":"Bello","year":"2011","journal-title":"her"},{"key":"R5-8-20211004","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/HJH.0b013e3283427c8b","article-title":"European Society of Hypertension Working Group on Obesity: obesity drugs and cardiovascular outcomes.","volume":"29","author":"Jordan","year":"2011","journal-title":"J Hypertens"},{"key":"R6-8-20211004","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1136\/bmj.39385.413113.25","article-title":"Long term pharmacotherapy for obesity and overweight: updated meta-analysis.","volume":"335","author":"Rucker","year":"2007","journal-title":"BMJ"},{"key":"R7-8-20211004","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1056\/NEJMoa050156","article-title":"Randomized trial of lifestyle modification and pharmacotherapy for obesity.","volume":"353","author":"Wadden","year":"2005","journal-title":"N Engl J Med"},{"key":"R8-8-20211004","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1185\/030079905X38132","article-title":"A review of the metabolic effects of sibutramine.","volume":"21","author":"Filippatos","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"R9-8-20211004","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1743-7075-6-42","article-title":"Differential changes in serum aric acid concentrations in sibutramine promoted weight loss in diabetes: results from four weeks of the lead-in period of the SCOUT trial.","volume":"6","author":"Andersson","year":"2009","journal-title":"Nutr Metab"},{"key":"R10-8-20211004","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1467-789X.2007.00425.x","article-title":"Sibutramine-associated adverse effects: a practical guide for its safe use.","volume":"9","author":"Florentin","year":"2008","journal-title":"Obes Rev"},{"key":"R11-8-20211004","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1093\/eurheartj\/ehm217","article-title":"Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT Trial.","volume":"28","author":"Torp-Pedersen","year":"2007","journal-title":"Eur Heart J"},{"key":"R12-8-20211004","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMoa1003114","article-title":"Effect of sibutramine on cardiovascular outcomes in overweight obese subjects.","volume":"363","author":"James","year":"2010","journal-title":"N Engl J Med"},{"key":"R13-8-20211004","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2165\/11532440-000000000-00000","article-title":"Fatal and non-fatal cardiovascular events in a general population prescribed sibutramine in New Zealand. A prospective cohort study.","volume":"33","author":"Harrison-Woolrych","year":"2010","journal-title":"Drug Saf"},{"key":"R14-8-20211004","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","article-title":"Effects of low-dose, controlled-release phentermine plus topiramate combination on weight and associated cormorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.","volume":"377","author":"Gadde","year":"2011","journal-title":"Lancet"},{"key":"R15-8-20211004","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes.","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"R17-8-20211004","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1093\/eurheartj\/ehp371","article-title":"Does abdominal obesity have a similar impact on cardiovascular disease and diabetes A study of 91, 246 ambulant patient in 27 European Countries.","volume":"30","author":"Fox","year":"2009","journal-title":"Eur Heart J"},{"key":"R18-8-20211004","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(10)60935-X","article-title":"Rimonabant for prevention of cardiovascular events (CREASCENDO): a randomized, multicentre, placebo-controlled trial.","volume":"376","author":"Topol","year":"2010","journal-title":"Lancet"},{"key":"R19-8-20211004","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1007\/s11096-010-9432-7","article-title":"Cardiovascular co-medication among users of antiobesity drugs: a population-based study.","volume":"32","author":"Amundsen","year":"2010","journal-title":"Pharm World Sci"},{"key":"R21-8-20211004","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1161\/ATVBAHA.109.196196","article-title":"Obesity genotype score and cardiovascular risk in women with type 2 diabetes mellitus.","volume":"30","author":"He","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R22-8-20211004","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1530\/EJE-10-0514","article-title":"Obesity-related cardiovascular risk factors after weight loss: a clinical trial comparing gastric bypass surgery and intensive lifestyle intervention.","volume":"163","author":"Hofso","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"R23-8-20211004","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.tips.2008.01.008","article-title":"Antiobesity drugs and neural circuits of feeding.","volume":"4","author":"Adan","year":"2008","journal-title":"Trends Pharmacol Sci"},{"key":"R24-8-20211004","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMp0805758","article-title":"Assessing the cardiovascular safety of diabetes therapies.","volume":"359","author":"Goldfine","year":"2008","journal-title":"N Engl J Med"},{"key":"R25-8-20211004","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1161\/CIRCULATIONAHA.108.767681","article-title":"Life and death in Denmark: lessons about diabetes and coronary heart disease.","volume":"117","author":"Goldfine","year":"2008","journal-title":"Circulation"},{"key":"R26-8-20211004","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1056\/NEJMe1007993","article-title":"Sibutramine: another flawed diet pill.","volume":"363","author":"Curfman","year":"2010","journal-title":"N Engl J Med"},{"key":"R27-8-20211004","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMp1010788","article-title":"Regulatory action on rosiglitazone by the US Food and Drug Administration.","volume":"363","author":"Woodcock","year":"2010","journal-title":"N Eng J Med"},{"key":"R28-8-20211004","first-page":"833","article-title":"Antiobesity drugs: to be or not to be Obes R","volume":"11","author":"Dvorak","year":"2010","journal-title":"ev"},{"key":"R29-8-20211004","first-page":"69","article-title":"Obesity in 2010: the future of obesity medicine - where do we go from here Nat Rev E","volume":"7","author":"Wright","year":"2011","journal-title":"ndocrinol"}],"container-title":["Current Opinion in Endocrinology, Diabetes & Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01266029-201110000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T01:43:08Z","timestamp":1633311788000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01266029-201110000-00008"}},"subtitle":["what did the Sibutramine Cardiovascular Outcomes Trial find?"],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/med.0b013e32834a8726","relation":{},"ISSN":["1752-296X"],"issn-type":[{"value":"1752-296X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}